Hsu K - Search Results

1

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM. Du J, et al. Among authors: hsu k. Cancer Immunol Res. 2014 Sep;2(9):878-89. doi: 10.1158/2326-6066.CIR-13-0158. Epub 2014 Jun 23. Cancer Immunol Res. 2014. PMID: 24958280 Free PMC article.

2

Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation.

Dupont B, Hsu KC. Dupont B, et al. Curr Opin Immunol. 2004 Oct;16(5):634-43. doi: 10.1016/j.coi.2004.07.013. Curr Opin Immunol. 2004. PMID: 15342011 Review.

3

KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro.

Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. Chewning JH, et al. J Immunol. 2007 Jul 15;179(2):854-68. doi: 10.4049/jimmunol.179.2.854. J Immunol. 2007. PMID: 17617576

4

Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.

Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Yu J, et al. J Immunol. 2007 Nov 1;179(9):5977-89. doi: 10.4049/jimmunol.179.9.5977. J Immunol. 2007. PMID: 17947671

5

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC. Yu J, et al. Blood. 2009 Apr 16;113(16):3875-84. doi: 10.1182/blood-2008-09-177055. Epub 2009 Jan 28. Blood. 2009. PMID: 19179302 Free PMC article.

6

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NK, Hsu KC. Venstrom JM, et al. Clin Cancer Res. 2009 Dec 1;15(23):7330-4. doi: 10.1158/1078-0432.CCR-09-1720. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934297 Free PMC article.

7

Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation.

Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf E, Hsu KC. Venstrom JM, et al. Blood. 2010 Apr 15;115(15):3162-5. doi: 10.1182/blood-2009-08-236943. Epub 2010 Feb 1. Blood. 2010. PMID: 20124216 Free PMC article.

8

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC. Tarek N, et al. J Clin Invest. 2012 Sep;122(9):3260-70. doi: 10.1172/JCI62749. Epub 2012 Aug 6. J Clin Invest. 2012. PMID: 22863621 Free PMC article.

9

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. Venstrom JM, et al. N Engl J Med. 2012 Aug 30;367(9):805-16. doi: 10.1056/NEJMoa1200503. N Engl J Med. 2012. PMID: 22931314 Free PMC article.

10

NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand.

Pittari G, Liu XR, Selvakumar A, Zhao Z, Merino E, Huse M, Chewning JH, Hsu KC, Dupont B. Pittari G, et al. J Immunol. 2013 May 1;190(9):4650-60. doi: 10.4049/jimmunol.1202120. Epub 2013 Apr 3. J Immunol. 2013. PMID: 23554313 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,833 results

Search Page